SCM
BHVN

Silverarc Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Silverarc Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,374
Closed -$3.84M – 108
2022
Q2 		$3.84M Sell
26,374
-76,123
-74% -$9.72M 1.8% 29
2022
Q1 		$4.36K Buy
102,497
+22,149
+28% +$2.76M 2.06% 14
2021
Q4 		$11.1M Buy
80,348
+18,451
+30% +$2.35M 4.96% 3
2021
Q3 		$8.6M Buy
61,897
+5,271
+9% +$658K 4.98% 1
2021
Q2 		$5.5K Buy
56,626
+6,537
+13% +$531K 2.68% 9
2021
Q1 		$3.42M Buy
50,089
+33,589
+204% +$2.72M 1.92% 20
2020
Q4 		$1.41M Buy
+16,500
New +$1.4M 0.86% 42

Other funds holding BHVN

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.37B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $7.94B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $7.29B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return